» Articles » PMID: 29196189

PD-L1, Inflammation, Non-coding RNAs, and Neuroblastoma: Immuno-oncology Perspective

Overview
Specialty Oncology
Date 2017 Dec 3
PMID 29196189
Citations 41
Authors
Affiliations
Soon will be listed here.
Abstract

Neuroblastoma is the most common pediatric solid tumor of neural crest origin. The current treatment options for neuroblastoma produce severe side effects. Programmed death-ligand 1 (PD-L1), chronic inflammation, and non-coding RNAs are known to play a significant role in the pathogenesis of neuroblastoma. Cancer cells and the surrounding cells in the tumor microenvironment express PD-L1. Programmed death-1 (PD-1) is a co-receptor expressed predominantly by T cells. The binding of PD-1 to its ligands, PD-L1 or PD-L2, is vital for the physiologic regulation of the immune system. Chronic inflammation is involved in the recruitment of leukocytes, production of cytokines and chemokines that in turn, lead to survival, metastasis, and angiogenesis in neuroblastoma tumors. The miRNAs and long non-coding (lnc) RNAs have emerged as a novel class of non-coding RNAs that can regulate neuroblastoma associated cell-signaling pathways. The dysregulation of PD-1/PD-L1, inflammatory pathways, lncRNAs, and miRNAs have been reported in clinical and experimental samples of neuroblastoma. These signaling molecules are currently being evaluated for their potential as the biomarker and therapeutic targets in the management of neuroblastoma. A monoclonal antibody called dinutuximab (Unituxin) that attaches to a carbohydrate molecule GD2, on the surface of many neuroblastoma cells, is being used as an immunotherapy drug for neuroblastoma treatment. Atezolizumab (Tecentriq), an engineered monoclonal antibody against PD-L1, are currently in clinical trial for neuroblastoma patients. The lncRNA/miRNA-based therapeutics is being developed to deliver tumor suppressor lncRNAs/miRNAs or silencing of oncogenic lncRNAs/miRNAs. The focus of this review is to discuss the current knowledge on the immune checkpoint molecules, PD-1/PD-L1 signaling, inflammation, and non-coding RNAs in neuroblastoma.

Citing Articles

Identification of lncRNA dual targeting PD-L1 and PD-L2 as a novel prognostic predictor for gastric cancer.

Zhang L, Chen J, Liu Y, Zhang Y, Hong L, Li X Front Oncol. 2024; 14:1341056.

PMID: 39525623 PMC: 11544118. DOI: 10.3389/fonc.2024.1341056.


Developing targeted therapies for neuroblastoma by dissecting the effects of metabolic reprogramming on tumor microenvironments and progression.

Jin W, Zhang Y, Zhao Z, Gao M Theranostics. 2024; 14(9):3439-3469.

PMID: 38948053 PMC: 11209723. DOI: 10.7150/thno.93962.


Long Non-Coding RNAs in Neuroblastoma: Pathogenesis, Biomarkers and Therapeutic Targets.

Vercouillie N, Ren Z, Terras E, Lammens T Int J Mol Sci. 2024; 25(11).

PMID: 38891878 PMC: 11171840. DOI: 10.3390/ijms25115690.


SESN1 functions as a new tumor suppressor gene via Toll-like receptor signaling pathway in neuroblastoma.

Hua Z, Chen B, Gong B, Lin M, Ma Y, Li Z CNS Neurosci Ther. 2024; 30(3):e14664.

PMID: 38516781 PMC: 10958400. DOI: 10.1111/cns.14664.


Systemic Immune-Inflammation Index May Predict Mortality in Neuroblastoma.

Banli Cesur I, Ozcelik Z Cureus. 2023; 15(3):e35705.

PMID: 36875247 PMC: 9982472. DOI: 10.7759/cureus.35705.


References
1.
Colvin E . Tumor-associated macrophages contribute to tumor progression in ovarian cancer. Front Oncol. 2014; 4:137. PMC: 4047518. DOI: 10.3389/fonc.2014.00137. View

2.
Szakacs G, Paterson J, Ludwig J, Booth-Genthe C, Gottesman M . Targeting multidrug resistance in cancer. Nat Rev Drug Discov. 2006; 5(3):219-34. DOI: 10.1038/nrd1984. View

3.
Mantovani A . Molecular pathways linking inflammation and cancer. Curr Mol Med. 2010; 10(4):369-73. DOI: 10.2174/156652410791316968. View

4.
Bach J, Rinn B, Meyer B, Dodel R, Bacher M . Role of MIF in inflammation and tumorigenesis. Oncology. 2008; 75(3-4):127-33. DOI: 10.1159/000155223. View

5.
Tee A, Liu B, Song R, Li J, Pasquier E, Cheung B . The long noncoding RNA MALAT1 promotes tumor-driven angiogenesis by up-regulating pro-angiogenic gene expression. Oncotarget. 2016; 7(8):8663-75. PMC: 4890995. DOI: 10.18632/oncotarget.6675. View